PSORIASIS VULGARIS

This study looks at how the drug tildrakizumab changes immune cells in the skin and blood of people with moderate-to-severe psoriasis. Ten adults will be treated and monitored for three months. The goal is to see how the drug reduces psoriasis severity and what happens to immune …

This study looks at how deucravacitinib, a drug that blocks a specific immune signal (TYK2), changes immune cells in the skin and blood of people with moderate-to-severe psoriasis. About 25 adults will take the drug and be monitored for improvements in their psoriasis symptoms. T…

This study tests whether measuring biologic drug levels in the blood can help doctors adjust doses for people with psoriasis. About 210 adults on certain biologics will either get dose advice based on blood tests or continue standard care. The goal is to maintain disease control …

This phase 3 trial tests a cream made from plant compounds (total coumarins) for treating psoriasis vulgaris. 300 adults will apply the cream or a placebo twice daily for 8 weeks. Researchers will check if the cream improves skin symptoms and quality of life, and monitor for side…

This study looks at whether a gene called vaspin, which is linked to fat tissue, plays a role in psoriasis. Researchers will compare blood samples and gene patterns from 60 people with psoriasis to see if certain gene changes are tied to more severe disease. The goal is to better…

This study is tracking 1,000 adults with psoriasis to see how their skin condition relates to heart disease. Researchers will use blood tests and heart imaging to find early signs of heart problems. The goal is to better understand why people with psoriasis have higher rates of h…